Open Orphan to start first-ever coronavirus challenge trial

0
42
  • Open Orphan delivers a double dose of contract good news
  • Open Orphan moves forward with government-backed COVID-19 vaccine human challenge study
  • Open Orphan announce ‘substantial contract wins’ with an existing client and UK government
Open Orphan

Quick facts: Open Orphan PLC

Follow

View company profile

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.

Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences and has offices in London, Dublin, Paris, and the Netherlands.

14 Jul 2021

(), the fast-growing pharma services specialist, has won two new lines of business.

Through its Breda office in the Netherlands, it landed a EUR900,000 contract for clinical trial services with an unnamed existing client which it describes as a “world leader in vaccine and antiviral testing”.

And in a separate announcement, it said the UK government is expanding a Coronavirus (COVID-19) characterisation study with the recruitment of a further 20 healthy volunteers “to answer further questions” that can help in the fight against the virus.

The research is taking place at London’s Royal Free Hospital under the supervision of scientists from the firm’s hVIVO operation. Work will get underway once regulatory approvals have been provided.

Read more

09 Jul 2021

() said its hVIVO subsidiary won a deal to test an antiviral in human challenge studies using the common cold and flu virus.

It will be working with Philadelphia-based AIM ImmunoTech’s drug Ampligen as part of a phase II trial, which is expected to kick off in the fourth quarter.

Read more

17 Jun 2021

() said it completed an important year of transition with an inflection point in the fourth quarter as it generated both an operating profit and positive cashflow, with full year profitability targeted for 2021.

Following the acquisition of hVIVO in January last year, the AIM-quoted contract research organisation said the integration with its Venn Life Sciences business was completed during the year, establishing it as the world leader in the testing of vaccines and antivirals through the use of human challenge study clinical trials.

Read more

21 Oct 2020

‘s () hVIVO arm has this week been confirmed as key player in the quest for a COVID-19 vaccine.

The business has just won a multi-million-pound UK government contract for human challenge studies, where healthy participants are exposed to the virus to get infected.

Read more

14 Jul 2021

() Cathal Friel joins Proactive London with the news that it has won two new lines of business landing a EUR900,000 contract for clinical trial services through its Breda office in the Netherlands.

The contract is with an unnamed existing client which it describes as a ‘world leader in vaccine and antiviral testing’.

Added to this the UK government is expanding a Coronavirus (COVID-19) characterisation study with the recruitment of a further 20 healthy volunteers to help in the fight against the virus.

02 Jun 2021

ORPH has firmly established its core pharma services offering, underpinned by the world-leading quarantine facilities, unique challenge study models and its established clinical trial services. ORPH is focusing on converting an extensive and substantial amount of non-Covid-19 related services worth over GBP100mln. This is in addition to substantial contracts already signed with the UK Government for COVID-19 vaccine challenge studies, pending finalisation of the characterisation study anticipated imminently. Furthermore, after extensive integration and restructuring in the past 18 months the company was finally profitable in the fourth quarter (Q4) of 2020 and continues during 2021 to perform very strongly according to plans. The company is also advancing its strategy of maximising the value of its non-core intellectual property (IP) assets to return value to existing shareholders. ORPH has received legal approval for a capital reduction relating to the current or future demerger of its non-core assets via spin-off into separately listed companies, to grant new share allotments or dividends, potentially crystallising the value of these assets.

Read full report



Download Research

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan announce ‘substantial contract wins’ with an existing client and…

Open Orphan PLC (LON:ORPH) Cathal Friel joins Proactive London with the news that it has won two new lines of business landing a EUR900,000 contract for clinical trial services through its Breda office in the Netherlands.

The contract is with an unnamed existing client which it describes…

8 hours, 47 minutes ago

2 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here